Yak did you get in at bargain .80-.82 and flip @ .90? If not why not? A win is a win …
R
Yakov has been on this board for a long and while i doubted him at first, he bring valuable points. Pnina does not care shareholders, let that sink in. If you can trade then that's it. Initial results were supposed to be in Q4 2021 , then postpone to Q1 2022 , now Q2 2022. Always remember, delay results is a negative , especially for that long. I made a mistake on this and i accept it. God luck
Y
The NASDAQ delisting process will start in short time. We are after collapse and before the failure announcement. No justification for this company existence IMHO.
D
We should be getting results from the phase 3 Piclidenoson study in Q2 2022.
s
Scored another gain albeit small …. That’s who Yak ….
C
CANF will soon announce oral top line results that exceed PHASE III endpoints. Why else would CANF announce the development of a topical version of the drug this morning. This is a tell if I have ever see one! BUY,BUY,BUY!!!
d
Can-Fite BioPharma (CANF) Receives a Buy from H.C. Wainwright
April 06 2022 - 06:25AM TipRanks
In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Can-Fite BioPharma (CANF – Research Report), with a price target of $5.00.
Y
CANF bruthal facts! The fraudsters delayed the Psoriasis trial results apparently failled by a Quarter to give them more time to prepare a new fairly tale story just and published and a new prospectus to dilute more at low prices. The Brutal fact about CANF technology is that it failed in 7 trials till now plus $200M evaporated. DYODD
Y
Toward the EVENT of Psoriasis trial results a blast from the past. This is a second try of the previous Psoriasis Failure. During 2014 the company published P2 Psoriasis trial results it looked BAD. The first time the fraudsters and scammers management published a failure and then after few days a 'correction' ..... actually they see that in certain individuals the result are cç GOOD!!! SOME INDIVIDUAL patients that can be identified by a Biomarker. Then the second time trial was born. To remind you.... Beware and DYODD
Dawson James analyst Jason Kolbert maintained a Buy rating on Can-Fite BioPharma (CANF – Research Report) on March 25 and set a price target of $9.00.
T
Canf breaks resistance . Up 17% in 3 days . Uptrend will continue as new results soon to be released
M
Wow..it seems only Yakov posting here how he is sad for other investors. In no time, you will see 1000s of new posts when day traders jump in when this pops up 300-400%.
R
Looking like this could be a very good year for canf.
s
Yak you want to make $$$ or you want to kvetch? Come profit with me . Looking
M
Yakov started on steroids this week. It is a good sign
d
CANF Provides Positive Clinical Update! Very Promising! 1.0899+0.0699 (+6.8529%) As of 11:30AM EDT. Market open.
s
Yak you missed yet another 20% gain! Learn to trade
d
1.2700+0.0800 (+6.72%) As of 11:04AM EDT. Market open. Hinting on positive Psoriasis results to come?
@ .90?
If not why not?
A win is a win …
That’s who Yak ….
April 06 2022 - 06:25AM
TipRanks
In a report released today, Vernon Bernardino from H.C. Wainwright
reiterated a Buy rating on Can-Fite BioPharma (CANF – Research Report),
with a price target of $5.00.
Pre-Market: 08:50AM EDT
Psoriasis results soon?
rating on Can-Fite BioPharma (CANF – Research Report)
on March 25 and set a price target of $9.00.
In no time, you will see 1000s of new posts when day traders jump in when this pops up 300-400%.
Come profit with me .
Looking
Very Promising!
1.0899+0.0699 (+6.8529%)
As of 11:30AM EDT. Market open.
Learn to trade
As of 11:04AM EDT. Market open.
Hinting on positive Psoriasis results to come?